(4-(perfluoroethyl)phenyl)methanol | 857297-30-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(perfluoroethyl)phenyl)methanol
• 英文别名: [4-(Pentafluoroethyl)phenyl]methanol；[4-(1,1,2,2,2-pentafluoroethyl)phenyl]methanol
• CAS: 857297-30-4
• 化学式: C₉H₇F₅O
• mdl: MFCD19439992
• 分子量: 226.146
• InChiKey: ZXZLUFRIKQUNAX-UHFFFAOYSA-N

物化性质

• 沸点：
  205.5±40.0 °C(Predicted)
• 密度：
  1.377±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (4-(perfluoroethyl)phenyl)methanol 在 水 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 ethyl (6-iodo-3-(3-methoxy-4-((4-(perfluoroethyl)benzyl)oxy)benzyl)-3H-imidazo[4,5-b]pyridin-2-yl)carbamate
  参考文献：
  名称：

  TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS

  摘要：

  Tropomyosin相关激酶抑制剂（Trk抑制剂）是治疗疾病的小分子化合物。Trk抑制剂可用作药物代理和药物组合物。Trk抑制剂在治疗炎症性疾病、自身免疫疾病、骨代谢缺陷和/或癌症方面非常有用，特别适用于骨关节炎（OA）、疼痛以及与OA相关的疼痛的治疗。Trk抑制剂还可用于抑制与肌浆蛋白相关的激酶A（TrkA）、与肌浆蛋白相关的激酶B（TrkB）、与肌浆蛋白相关的激酶C（TrkC）和/或c-FMS（促红细胞生成因子-1（CSF-1）的细胞受体）有关的作用。

  公开号：

  US20150158847A1

文献信息

• Tropomyosin-related kinase (TRK) inhibitors
  申请人：Genzyme Corporation

  公开号：US09067914B1

  公开（公告）日：2015-06-30

  Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

  Tropomyosin-related kinase inhibitors (Trk抑制剂)是一种小分子化合物，可用于治疗疾病。Trk抑制剂可作为药物剂量和药物组成部分使用。Trk抑制剂在治疗炎症性疾病、自身免疫疾病、骨代谢缺陷和/或癌症方面非常有用，尤其在治疗骨关节炎（OA）、疼痛以及与OA相关的疼痛方面特别有用。Trk抑制剂还可用于抑制与肿瘤相关的蛋白激酶A、B、C和/或c-FMS（促红细胞生成素-1（CSF-1）的细胞受体）。
• Tropomyosin-related kinase (Trk) inhibitors
  申请人：Genzyme Corporation

  公开号：US09174986B2

  公开（公告）日：2015-11-03

  Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

  Tropomyosin-related kinase抑制剂（Trk抑制剂）是治疗疾病的小分子化合物。Trk抑制剂可用作制药剂和制药组合物。Trk抑制剂对治疗炎症性疾病、自身免疫疾病、骨代谢缺陷和/或癌症有用，尤其对于治疗骨关节炎（OA）、疼痛和与OA相关的疼痛特别有用。Trk抑制剂还可用于抑制肌动蛋白相关激酶A（TrkA）、肌动蛋白相关激酶B（TrkB）、肌动蛋白相关激酶C（TrkC）和/或c-FMS（集落刺激因子-1（CSF-1）的细胞受体）。
• Tropomyosin-Related Kinase (TRK) Inhibitors
  申请人：Genzyme Corporation

  公开号：US20210169894A1

  公开（公告）日：2021-06-10

  Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
• US9067914B1
  申请人：——

  公开号：US9067914B1

  公开（公告）日：2015-06-30
• US9174986B2
  申请人：——

  公开号：US9174986B2

  公开（公告）日：2015-11-03